Work with thought leaders and academic experts in oncology

Companies can greatly benefit from working with an expert in the field of Oncology. Here are a few reasons why: 1. Cutting-edge Research: Oncology experts stay updated with the latest advancements in cancer research, providing valuable insights and innovative solutions. 2. Clinical Trials: Collaborating with an Oncology researcher allows companies to conduct clinical trials, accelerating the development of new treatments and therapies. 3. Expertise in Precision Medicine: Oncology researchers specialize in personalized medicine, helping companies develop targeted therapies based on individual patient characteristics. 4. Access to Networks: Academic researchers in Oncology have extensive networks within the medical community, providing access to key opinion leaders, clinicians, and other experts. 5. Regulatory Compliance: Oncology experts are well-versed in regulatory requirements, ensuring companies meet all necessary guidelines and standards.

Experts on NotedSource with backgrounds in oncology include Dushani L. Palliyaguru, Ph.D., Ramy Ayoub, Michael W Harman, Luca Delfinis, Boris Leibovitch, Jeffrey Townsend, Athul Prasad, Liam D. Hendrikse, Ph.D., Giuliana Noratto, Marina Baretti, Abiodun Adewuya, Ramy Ayoub, Timothy Sears, Katelyn Katelyn Masiuk, Kayvan Najarian, Amir Manbachi, Jens Hegg, Olivier Saulnier, AMAN SHARMA, Mehrdad Sheikhvatan, Niko Popitsch, Sitapriya Moorthi, Jonathan Eby, and Zinaida Good.

Ramy Ayoub

Toronto, Ontario, Canada
PhD Candidate Medical Biophysics
Most Relevant Research Interests
Oncology
Oncology
Other Research Interests (17)
neuro-oncology
mouse imaging
cancer therapy
normal tissue toxicity
Multidisciplinary
And 12 more
About
Ramy Ayoub is a PhD candidate at the University of Toronto in the department of Medical Biophysics. His research focuses on the development of treatment strategies to limit long-term negative complications in brain tumour survivors treated with radiation therapy. Ramy addresses his thesis work by conducting genetic, pharmacological, and neuroimaging studies on mouse models for paediatric radiotherapy. Ramy has authored numerous scientific publications and is a recipient of several awards, including the Brain Star award for excellence in Canadian research. Ramy has passion for advancing science innovation through collaborative efforts across academia and industry.
Most Relevant Publications (2+)

7 total publications

QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY

Neuro-Oncology / Jun 01, 2018

Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634

MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma

Neuro-Oncology / Jun 01, 2022

Smith, K., Bihannic, L., Gudenas, B., Gao, Q., Haldipur, P., Tao, R., Iskusnykh, I., Chizhikov, V., Scoggins, M., Zhang, S., Edwards, A., Deng, M., Glass, I., Overman, L., Millman, J., Sjoboen, A., Hadley, J., Mankad, K., Onar-Thomas, A., … Northcott, P. (2022). MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 24(Supplement_1), i124–i125. https://doi.org/10.1093/neuonc/noac079.452

Michael W Harman

East Greenwich, RI, Rhode Island, United States of America
Distinguished Subject Matter Expert & Leader in Medical Technologies.
Most Relevant Research Interests
Oncology
Oncology
Other Research Interests (15)
Bacteria & Cell Bio-Physics
Biomechanics
Infectious Diseases
Immunology
Microbiology
And 10 more
About
Highly skilled, energetic, and motivated professional empowered by over a decade of cross-disciplinary engineering and scientific applications experience. Presenting elegant solutions to prevalent biomedical challenges. Motivated by driving deliverable outcomes from complex research studies through effective leadership, active consulting work, and innovative problem-solving techniques. Seeking to make an immediate impact in a fast-paced biotechnology environment capitalizing on my advanced comprehension, continued professional growth, strategic product development expertise, and active network of personal connections across all areas of science, engineering, medicine, manufacturing and healthcare.
Most Relevant Publications (2+)

15 total publications

Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells

Cancer Research / Jul 15, 2016

Gomes, C. J., Harman, M., Centuori, S., Wolgemuth, C., & Martinez, J. (2016). Abstract 3591: Expression of 14-3-3 gamma stabilizes polyploidization in NSCLC cells. Cancer Research, 76(14_Supplement), 3591–3591. https://doi.org/10.1158/1538-7445.am2016-3591

Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers

Cancer Research / Aug 01, 2015

Gomes, C. J., Harman, M., Martinez, J., & Centuori, S. (2015). Abstract 2066: Aberrant upregulation of 14-3-3 gamma promotes mononucleated polyploidization in human lung cancers. Cancer Research, 75(15_Supplement), 2066–2066. https://doi.org/10.1158/1538-7445.am2015-2066

Boris Leibovitch

New York, New York, United States of America
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Interests
Oncology
Other Research Interests (11)
Cancer Research
Cell Biology
Developmental Biology
Molecular Biology
Multidisciplinary
And 6 more
About
I am experienced molecular and cell biologist with deep genetics background who worked many years in USA and Russia on the bench and as teacher. Both types of work had demanded extremely broad knowledge and understanding of developments in the fields. Participation in grant writing, editorial/reviewer work for scientific journals and consulting colleagues on these subjects added a lot to my broad experience as the scientist.
Most Relevant Publications (5+)

22 total publications

Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells

Oncotarget / Aug 19, 2016

Kwon, Y.-J., Leibovitch, B. A., Bansal, N., Pereira, L., Chung, C.-Y., Ariztia, E. V., Zelent, A., Farias, E. F., & Waxman, S. (2016). Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells. Oncotarget, 8(51), 88421–88436. https://doi.org/10.18632/oncotarget.11381

Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer

Oncotarget / Jun 07, 2016

Bansal, N., Bosch, A., Leibovitch, B., Pereira, L., Cubedo, E., Yu, J., Pierzchalski, K., Jones, J. W., Fishel, M., Kane, M., Zelent, A., Waxman, S., & Farias, E. (2016). Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer. Oncotarget, 7(28), 43689–43702. https://doi.org/10.18632/oncotarget.9905

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Molecular Cancer Therapeutics / Aug 01, 2015

Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t

Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer

Oncotarget / Oct 09, 2015

Bansal, N., Petrie, K., Christova, R., Chung, C.-Y., Leibovitch, B. A., Howell, L., Gil, V., Sbirkov, Y., Lee, E., Wexler, J., Ariztia, E. V., Sharma, R., Zhu, J., Bernstein, E., Zhou, M.-M., Zelent, A., Farias, E., & Waxman, S. (2015). Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer. Oncotarget, 6(33), 34087–34105. https://doi.org/10.18632/oncotarget.6048

Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1

Translational Oncology / Feb 01, 2022

Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320

Jeffrey Townsend

New Haven, CT
Professor of Biostatistics and Ecology & Evolutionary Biology
Most Relevant Research Interests
Oncology
Other Research Interests (78)
Statistics
cancer genetics
disease modeling
antibiotic resistance
Evolutionary Genomics
And 73 more
About
Jeffrey Townsend is a Professor of Organismic and Evolutionary Biology at Yale University. He received his Ph.D. from Harvard University in 2002 and his Sc.B. from Brown University in 1994. He has been a teacher at St. Ann's School and an Assistant Professor at the University of Connecticut. He is currently the Elihu Professor of Biostatistics at Yale University.
Most Relevant Publications (21+)

207 total publications

Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR

Cancer Research / Dec 05, 2022

Mandell, J. D., Cannataro, V. L., & Townsend, J. P. (2022). Estimation of Neutral Mutation Rates and Quantification of Somatic Variant Selection Using cancereffectsizeR. Cancer Research, 83(4), 500–505. https://doi.org/10.1158/0008-5472.can-22-1508

In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report”

JTO Clinical and Research Reports / Dec 01, 2022

Moore, M., Zhuo, Y., Mandell, J. D., Gaffney, S. G., & Townsend, J. P. (2022). In Response to “De Novo KRAS G12C-Mutant SCLC: A Case Report.” JTO Clinical and Research Reports, 3(12), 100418. https://doi.org/10.1016/j.jtocrr.2022.100418

Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia

Leukemia / Nov 11, 2022

Mandell, J. D., Fisk, J. N., Cyrenne, E., Xu, M. L., Cannataro, V. L., & Townsend, J. P. (2022). Not only mutations but also tumorigenesis can be substantially attributed to DNA damage from reactive oxygen species in RUNX1::RUNX1T1-fusion-positive acute myeloid leukemia. Leukemia, 36(12), 2931–2933. https://doi.org/10.1038/s41375-022-01752-5

Cancer Relevance of Human Genes

JNCI: Journal of the National Cancer Institute / Apr 13, 2022

Qing, T., Mohsen, H., Cannataro, V. L., Marczyk, M., Rozenblit, M., Foldi, J., Murray, M., Townsend, J. P., Kluger, Y., Gerstein, M., & Pusztai, L. (2022). Cancer Relevance of Human Genes. JNCI: Journal of the National Cancer Institute, 114(7), 988–995. https://doi.org/10.1093/jnci/djac068

Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study

The Lancet Regional Health - Europe / Mar 01, 2022

Wells, C. R., Pandey, A., Fitzpatrick, M. C., Crystal, W. S., Singer, B. H., Moghadas, S. M., Galvani, A. P., & Townsend, J. P. (2022). Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study. The Lancet Regional Health - Europe, 14, 100304. https://doi.org/10.1016/j.lanepe.2021.100304

Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma

Cancer Letters / Feb 01, 2022

Fisk, J. N., Mahal, A. R., Dornburg, A., Gaffney, S. G., Aneja, S., Contessa, J. N., Rimm, D., Yu, J. B., & Townsend, J. P. (2022). Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma. Cancer Letters, 526, 346–351. https://doi.org/10.1016/j.canlet.2021.11.011

Environmental and sex-specific molecular signatures of glioma causation

Neuro-Oncology / May 04, 2021

Claus, E. B., Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2021). Environmental and sex-specific molecular signatures of glioma causation. Neuro-Oncology, 24(1), 29–36. https://doi.org/10.1093/neuonc/noab103

Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden

Lung Cancer / Apr 01, 2022

Tan, C., Mandell, J. D., Dasari, K., Cannataro, V. L., Alfaro-Murillo, J. A., & Townsend, J. P. (2022). Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors—on average—to exhibit a lower mutation burden. Lung Cancer, 166, 265–269. https://doi.org/10.1016/j.lungcan.2021.10.008

Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers

Bladder Cancer / Jun 11, 2020

Yang, A., Cross, C. N., & Townsend, J. P. (2020). Non-Coding Mutations in Urothelial Bladder Cancer: Biological and Clinical Relevance and Potential Utility as Biomarkers. Bladder Cancer, 6(2), 211–213. https://doi.org/10.3233/blc-200278

Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma

Oral Oncology / Feb 01, 2020

Lu, L., Gaffney, S. G., Cannataro, V. L., & Townsend, J. (2020). Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. Oral Oncology, 101, 104554. https://doi.org/10.1016/j.oraloncology.2019.104554

The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment

Oncotarget / Jul 16, 2019

Gaffney, S. G., Perry, E. B., Chen, P.-M., Greenstein, A., Kaech, S. M., & Townsend, J. P. (2019). The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. Oncotarget, 10(44), 4532–4545. https://doi.org/10.18632/oncotarget.27027

Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck

Clinical Cancer Research / Jun 01, 2019

Lee, J. W., Parameswaran, J., Sandoval-Schaefer, T., Eoh, K. J., Yang, D., Zhu, F., Mehra, R., Sharma, R., Gaffney, S. G., Perry, E. B., Townsend, J. P., Serebriiskii, I. G., Golemis, E. A., Issaeva, N., Yarbrough, W. G., Koo, J. S., & Burtness, B. (2019). Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 25(11), 3430–3442. https://doi.org/10.1158/1078-0432.ccr-18-0440

Somatic evolutionary timings of driver mutations

BMC Cancer / Jan 18, 2018

Gomez, K., Miura, S., Huuki, L. A., Spell, B. S., Townsend, J. P., & Kumar, S. (2018). Somatic evolutionary timings of driver mutations. BMC Cancer, 18(1). https://doi.org/10.1186/s12885-017-3977-y

Effect Sizes of Somatic Mutations in Cancer

JNCI: Journal of the National Cancer Institute / Oct 26, 2018

Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018). Effect Sizes of Somatic Mutations in Cancer. JNCI: Journal of the National Cancer Institute, 110(11), 1171–1177. https://doi.org/10.1093/jnci/djy168

Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials

Oncotarget / Apr 27, 2018

Wilkins, J. F., Cannataro, V. L., Shuch, B., & Townsend, J. P. (2018). Analysis of mutation, selection, and epistasis: an informed approach to cancer clinical trials. Oncotarget, 9(32), 22243–22253. https://doi.org/10.18632/oncotarget.25155

CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma

Frontiers in Oncology / Apr 04, 2018

Chen, W. S., Bindra, R. S., Mo, A., Hayman, T., Husain, Z., Contessa, J. N., Gaffney, S. G., Townsend, J. P., & Yu, J. B. (2018). CDKN2A Copy Number Loss Is an Independent Prognostic Factor in HPV-Negative Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 8. https://doi.org/10.3389/fonc.2018.00095

PhyloOncology: Understanding cancer through phylogenetic analysis

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer / Apr 01, 2017

Somarelli, J. A., Ware, K. E., Kostadinov, R., Robinson, J. M., Amri, H., Abu-Asab, M., Fourie, N., Diogo, R., Swofford, D., & Townsend, J. P. (2017). PhyloOncology: Understanding cancer through phylogenetic analysis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1867(2), 101–108. https://doi.org/10.1016/j.bbcan.2016.10.006

Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function

Annals of Oncology / Jan 01, 2017

Choi, M., Kadara, H., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Kim, K., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Wistuba, I. I. (2017). Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Annals of Oncology, 28(1), 83–89. https://doi.org/10.1093/annonc/mdw437

Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up

Annals of Oncology / Jan 01, 2017

Kadara, H., Choi, M., Zhang, J., Parra, E. R., Rodriguez-Canales, J., Gaffney, S. G., Zhao, Z., Behrens, C., Fujimoto, J., Chow, C., Yoo, Y., Kalhor, N., Moran, C., Rimm, D., Swisher, S., Gibbons, D. L., Heymach, J., Kaftan, E., Townsend, J. P., … Herbst, R. S. (2017). Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Annals of Oncology, 28(1), 75–82. https://doi.org/10.1093/annonc/mdw436

Inferring the Origin of Metastases from Cancer Phylogenies

Cancer Research / Sep 30, 2015

Hong, W. S., Shpak, M., & Townsend, J. P. (2015). Inferring the Origin of Metastases from Cancer Phylogenies. Cancer Research, 75(19), 4021–4025. https://doi.org/10.1158/0008-5472.can-15-1889

Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets

International Journal of Radiation Oncology*Biology*Physics / May 01, 2017

Chen, W. S., Townsend, J. P., & Yu, J. B. (2017). Radiation-Specific Clinical Data Should Be Included in Existing Large-Scale Genomic Datasets. International Journal of Radiation Oncology*Biology*Physics, 98(1), 8–10. https://doi.org/10.1016/j.ijrobp.2017.01.023

Liam D. Hendrikse, Ph.D.

Toronto, Ontario, Canada
Bioinformatician at the University Health Network in Toronto, CA, specializing in computational cancer research using various sequencing modalities.
Most Relevant Research Interests
Oncology
Other Research Interests (14)
Medulloblastoma
Bioinformatics
Genomics
Multidisciplinary
General Biochemistry, Genetics and Molecular Biology
And 9 more
About
Liam Hendrikse is a recent Ph.D. graduate from the Department of Medical Biophysics at the University of Toronto, now working as a Bioinformatician at the University Health Network. His research focuses on deepening our understanding of various cancer types using computational methods, in order to develop novel treatment options. Liam has a particular strength in analysis of various single-cell sequencing technologies (RNA, ATAC, CITE, TCR/BCR, etc.), as well as traditional sequencing technologies, such as bulk RNAseq. Liam has a proven track record of deriving highly impactful biological insights through his research, as evidenced by publications in high impact journals such as Nature and Cancer Discovery. Previously, Liam earned his Bachelor of Science in biochemistry and immunology from Western University in 2018.
Most Relevant Publications (4+)

10 total publications

H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone

Cancer Discovery / Dec 01, 2020

Khazaei, S., De Jay, N., Deshmukh, S., Hendrikse, L. D., Jawhar, W., Chen, C. C. L., Mikael, L. G., Faury, D., Marchione, D. M., Lanoix, J., Bonneil, É., Ishii, T., Jain, S. U., Rossokhata, K., Sihota, T. S., Eveleigh, R., Lisi, V., Harutyunyan, A. S., Jung, S., … Jabado, N. (2020). H3.3 G34W Promotes Growth and Impedes Differentiation of Osteoblast-Like Mesenchymal Progenitors in Giant Cell Tumor of Bone. Cancer Discovery, 10(12), 1968–1987. https://doi.org/10.1158/2159-8290.cd-20-0461

MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS

Neuro-Oncology / Jun 01, 2023

Qadeer, Z., Westelman, S., Johnson, M., Grele, S., Hou, E., Hendrikse, L., Wang, L., Husain, S., Beytagh, M. C., Schmidt, C., Huang, M., Taylor, M., & Weiss, W. (2023). MDB-07. MYC AND TGFΒ PROMOTE GROUP 3 MEDULLOBLASTOMA TUMOR RESISTANCE THROUGH DEREGULATION OF KDM2B TARGETS. Neuro-Oncology, 25(Supplement_1), i62–i63. https://doi.org/10.1093/neuonc/noad073.240

MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA

Neuro-Oncology / Jun 01, 2023

Saulnier, O., Zagozewski, J., Liang, L., Hendrikse, L. D., Gordon, V., Aldinger, K. A., Haldipur, P., Borlase, S., Coudiere-Morrison, L., Layug, P., Cai, T., Porter, C. J., Richard, S., Doble, B. W., Millen, K. J., Taylor, M. D., & Werbowetski-Ogilvie, T. E. (2023). MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i66–i67. https://doi.org/10.1093/neuonc/noad073.254

DDDR-33. TARGETING TGFΒ PATHWAY DEPENDENCIES IN GROUP 3 MEDULLOBLASTOMA

Neuro-Oncology / Nov 01, 2022

Qadeer, Z., Westelman, S., Johnson, M., Grele, S., Hendrikse, L., Taylor, M., & Weiss, W. (2022). DDDR-33. TARGETING TGFΒ PATHWAY DEPENDENCIES IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 24(Supplement_7), vii106–vii106. https://doi.org/10.1093/neuonc/noac209.398

Giuliana Noratto

Food Scientist PhD and Registered Dietician - Texas A&M University
Most Relevant Research Interests
Oncology
Other Research Interests (49)
Food Science
human nutrition
disease prevention and treatment
Nutrition
Human Health
And 44 more
About
Dr. Giuliana Noratto is a senior associate research scientist at Texas A&M AgriLife. She received her Ph.D. in food science and technology from Texas A&M University System, and her M.Sc. in food science and technology from Universidad Nacional Agraria La Molina. She also holds a B.S. in food science and technology from Universidad Nacional Agraria La Molina. Dr. Noratto’s research interests include food safety and quality, sensory science, and food processing.
Most Relevant Publications (2+)

91 total publications

Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation

Nutrition and Cancer / Sep 14, 2020

Layosa, M. A. A., Lage, N. N., Chew, B. P., Atienza, L., Mertens-Talcott, S., Talcott, S., & Noratto, G. D. (2020). Dark Sweet Cherry (Prunus avium) Phenolics Enriched in Anthocyanins Induced Apoptosis in MDA-MB-453 Breast Cancer Cells through MAPK-Dependent Signaling and Reduced Invasion via Akt and PLCγ-1 Downregulation. Nutrition and Cancer, 73(10), 1985–1997. https://doi.org/10.1080/01635581.2020.1817514

Pro-Apoptotic Activities of Polyphenolics From Açai (Euterpe oleraceaMartius) in Human SW-480 Colon Cancer Cells

Nutrition and Cancer / Oct 20, 2014

Dias, M. M. dos S., Noratto, G., Martino, H. S. D., Arbizu, S., Peluzio, M. do C. G., Talcott, S., Ramos, A. M., & Mertens-Talcott, S. U. (2014). Pro-Apoptotic Activities of Polyphenolics From Açai (Euterpe oleraceaMartius) in Human SW-480 Colon Cancer Cells. Nutrition and Cancer, 66(8), 1394–1405. https://doi.org/10.1080/01635581.2014.956252

Marina Baretti

Baltimore, Maryland, United States of America
I am a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions.
Most Relevant Research Interests
Oncology
Other Research Interests (19)
Pharmacology (medical)
Pharmacology
Hematology
Gastroenterology
Hepatology
And 14 more
About
Throughout my training, I have been focused toward my ultimate goal of becoming a clinical translational researcher in gastrointestinal (GI) oncology, collaborating closely with laboratory-based researchers to move laboratory findings into patients and to answer important clinical questions. My clinical research is centered on the development of novel agents in GI cancers, with particular interest in combinatorial approaches of epigenetic therapies and immunotherapies combinations. I ran the first phase II study of combination epigenetic therapy and immunotherapy in advanced pancreatic adenocarcinoma and cholangiocarcinoma, working with a collaborative team that incorporates leading experts in cancer immunology, epigenetics and drug development. I was awarded the 2018 ASCO Conquer Cancer Foundation Young Investigator Award for this project.  Together with Dr. Yarchoan, we are running a clinical trial of a novel neoantigen-specific vaccine in combination with immune checkpoint inhibitors for advanced fibrolamellar carcinoma (FLC) (NCT04248569). My laboratory focus has been on developing and validating a preclinical mouse model of FLC to investigate mechanisms underlying FLC pathogenesis, and will become a critical tool for investigating novel therapeutic strategies in FLC.
Most Relevant Publications (43+)

57 total publications

Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer

Immunotherapy / Jul 01, 2020

Rossi, S., Toschi, L., Finocchiaro, G., & Santoro, A. (2020). Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer. Immunotherapy, 12(10), 715–724. https://doi.org/10.2217/imt-2019-0154

The role of epigenetic therapies in colorectal cancer

Current Problems in Cancer / Nov 01, 2018

Baretti, M., & Azad, N. S. (2018). The role of epigenetic therapies in colorectal cancer. Current Problems in Cancer, 42(6), 530–547. https://doi.org/10.1016/j.currproblcancer.2018.03.001

Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram

Annals of Oncology / Mar 01, 2017

Pietrantonio, F., Miceli, R., Rimassa, L., Lonardi, S., Aprile, G., Mennitto, A., Marmorino, F., Bozzarelli, S., Antonuzzo, L., Tamburini, E., Morano, F., Rossini, D., Battaglin, F., Baretti, M., Berenato, R., Formica, V., Mosconi, S., Petrelli, F., Ghidini, M., … Cremolini, C. (2017). Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. Annals of Oncology, 28(3), 555–561. https://doi.org/10.1093/annonc/mdw627

KRAS mutation in lung metastases from colorectal cancer: prognostic implications

Cancer Medicine / Dec 29, 2015

Ghidini, M., Personeni, N., Bozzarelli, S., Baretti, M., Basso, G., Bianchi, P., Tronconi, M. C., Pressiani, T., Grizzi, F., Giordano, L., Malesci, A., Alloisio, M., Laghi, L., Santoro, A., & Rimassa, L. (2015). <scp>KRAS</scp> mutation in lung metastases from colorectal cancer: prognostic implications. Cancer Medicine, 5(2), 256–264. Portico. https://doi.org/10.1002/cam4.592

Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma

Immunotherapy / Dec 01, 2016

Simonelli, M., Di Tommaso, L., Baretti, M., & Santoro, A. (2016). Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. Immunotherapy, 8(12), 1363–1369. https://doi.org/10.2217/imt-2016-0057

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures

JCO Precision Oncology / Jun 01, 2022

Mody, K., Jain, P., El-Refai, S. M., Azad, N. S., Zabransky, D. J., Baretti, M., Shroff, R. T., Kelley, R. K., El-Khouiery, A. B., Hockenberry, A. J., Lau, D., Lesinski, G. B., & Yarchoan, M. (2022). Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. JCO Precision Oncology, 6. https://doi.org/10.1200/po.21.00510

Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities

Annals of Pancreatic Cancer / Oct 01, 2019

Baretti, M., Ahuja, N., & Azad, N. S. (2019). Targeting the epigenome of pancreatic cancer for therapy: challenges and opportunities. Annals of Pancreatic Cancer, 2, 18–18. https://doi.org/10.21037/apc.2019.10.01

Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.

Journal of Clinical Oncology / May 20, 2018

Baretti, M., Durham, J. N., Walker, R., Mitcheltree, A.-L., Christmas, B., Cope, L., Jaffee, E. M., & Azad, N. S. (2018). Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma. Journal of Clinical Oncology, 36(15_suppl), TPS4151–TPS4151. https://doi.org/10.1200/jco.2018.36.15_suppl.tps4151

Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic

Cancer Control / Jan 01, 2021

Jia, A. Y., Popovic, A., Mohan, A. A., Zorzi, J., Griffith, P., Kim, A. K., Anders, R. A., Burkhart, R. A., Lafaro, K., Georgiades, C., Azad, N. S., Liddell, R. P., Baretti, M., Kamel, I. R., Narang, A., Yarchoan, M., & Meyer, J. (2021). Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic. Cancer Control, 28, 107327482110099. https://doi.org/10.1177/10732748211009945

Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection

OncoImmunology / Jan 01, 2021

Delitto, D., Zabransky, D. J., Chen, F., Thompson, E. D., Zimmerman, J. W., Armstrong, T. D., Leatherman, J. M., Suri, R., Lopez-Vidal, T. Y., Huff, A. L., Lyman, M. R., Guinn, S. R., Baretti, M., Kagohara, L. T., Ho, W. J., Azad, N. S., Burns, W. R., He, J., Wolfgang, C. L., … Jaffee, E. M. (2021). Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. OncoImmunology, 10(1). https://doi.org/10.1080/2162402x.2021.2001159

Expanding the immunotherapy roadmap for hepatocellular carcinoma

Cancer Cell / Mar 01, 2022

Baretti, M., Kim, A. K., & Anders, R. A. (2022). Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell, 40(3), 252–254. https://doi.org/10.1016/j.ccell.2022.02.017

Precision Cancer Trials With Immunomodulatory Agents

The Cancer Journal / Jul 01, 2019

Baretti, M., & Azad, N. S. (2019). Precision Cancer Trials With Immunomodulatory Agents. The Cancer Journal, 25(4), 287–295. https://doi.org/10.1097/ppo.0000000000000390

Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND)

Annals of Oncology / Oct 01, 2016

Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). Regorafenib in patients with refractory metastatic pancreatic cancer. An open-label phase II study (RESOUND). Annals of Oncology, 27, vi233. https://doi.org/10.1093/annonc/mdw371.84

Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer

Annals of Oncology / Sep 01, 2014

Sefrioui, D., Vasseur, C., Sesboué, R., Blanchard, F., Gangloff, A., Baretti, M., Beaussire, L., Clatot, F., Dolfus, C., Sabourin, J., Michel, P., Frebourg, T., & Di Fiore, F. (2014). Clinical Interest of Digital Pcr for Routine Detection of Circulating Dna in Metastatic Colorectal Cancer. Annals of Oncology, 25, iv559. https://doi.org/10.1093/annonc/mdu358.48

Modified Folfoxiri in advanced Pancreatic Cancer

Annals of Oncology / Sep 01, 2012

Ginocchi, L., Vasile, E., Caponi, S., Lucchesi, M., Caparello, C., Da Prat, V., Baretti, M., Lencioni, M., Ricci, S., & Falcone, A. (2012). Modified Folfoxiri in advanced Pancreatic Cancer. Annals of Oncology, 23, ix238. https://doi.org/10.1016/s0923-7534(20)33292-0

TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)

Annals of Oncology / Sep 01, 2012

Borad, M., Reddy, S., Bahary, N., Uronis, H., Sigal, D. S., Cohn, A. L., Schelman, W., Stephenson, J., Eng, C., & Ryan, D. P. (2012). TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC). Annals of Oncology, 23, ix224. https://doi.org/10.1093/annonc/mds398

Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

Cancers / Oct 30, 2022

Chen, K. Y., Popovic, A., Hsiehchen, D., Baretti, M., Griffith, P., Bista, R., Baghdadi, A., Kamel, I. R., Simon, S. M., Migler, R. D., & Yarchoan, M. (2022). Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 14(21), 5347. https://doi.org/10.3390/cancers14215347

1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence

Annals of Oncology / Sep 01, 2021

Heumann, T. R., Baretti, M., Sugar, E., Durhman, J., Liden, S., Miles, T., Lopez-Vidal, T. Y., Leatherman, J., Sharma, A., Ahuja, N., Weekes, C. D., O’Dwyer, P. J., Monga, D. K., Reiss Binder, K. A., & Azad, N. (2021). 1470P Oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Annals of Oncology, 32, S1087–S1088. https://doi.org/10.1016/j.annonc.2021.08.797

Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram

Annals of Oncology / Sep 01, 2017

Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Morano, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., Miceli, R., & Aprile, G. (2017). Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram. Annals of Oncology, 28, v227. https://doi.org/10.1093/annonc/mdx369.052

ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND

Annals of Oncology / Oct 01, 2015

Bozzarelli, S., Rimassa, L., Giordano, L., Garassino, I., Marrari, A., Tronconi, M. C., De Sanctis, R. M., Cavina, R., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2015). ONC-2014-001: An open-label phase II study of regorafenib in patients with metastatic solid tumors who have progressed after standard therapy - RESOUND. Annals of Oncology, 26, vi150. https://doi.org/10.1093/annonc/mdv348.59

Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment

Cancer Research / Apr 04, 2023

Kamdar, Z., Lopez-Vidal, T., Howe, K., Munjal, K., Saeed, A., Zabransky, D., Shu, D., Longway, G., Kartalia, E., Leatherman, J., Mohan, A., Khare, P., Zhang, C., Le, A., Pearce, E., Furth, M., Baretti, M., Leone, R., Jaffee, E., & Yarchoan, M. (2023). Abstract 3679: DNAJB1-PRKACA fusion in fibrolamellar hepatocellular carcinoma induces glutamine addiction and an immunosuppressive tumor microenvironment. Cancer Research, 83(7_Supplement), 3679–3679. https://doi.org/10.1158/1538-7445.am2023-3679

Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer

Oncotarget / Jul 28, 2022

Baretti, M., Zhu, Q., Fu, W., Meyer, J., Wang, H., Anders, R. A., & Azad, N. S. (2022). Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer. Oncotarget, 13(1), 907–917. https://doi.org/10.18632/oncotarget.28255

SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus

Annals of Oncology / Oct 01, 2019

De Jesus-Acosta, A., Crespo Herrero, G., Gómez-Dorronsoro, M. L., Alonso, V., Riesco Martinez, M. C., Custodio, A., Lopez, C., Benavent, M., Carmona Bayonas, A., Jimenez-Fonseca, P., Llanos, M., López De San Vicente, B., Arrazubi Arrula, V., Grandez, R., González-Borja, I., Goñi, S., Arozarena, I., Baretti, M., & Viudez, A. (2019). SILVELUL project: Immunohistochemical panel analyses as potential predictive and prognostic factors in pancreatic neuroendocrine tumours (PanNET) treated with CAPTEM or everolimus. Annals of Oncology, 30, v196. https://doi.org/10.1093/annonc/mdz245.006

Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer.

Journal of Clinical Oncology / Feb 01, 2019

Baretti, M., Fu, W., Wang, H., Anders, R. A., Azad, N. S., & Zhu, Q. (2019). Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer. Journal of Clinical Oncology, 37(4_suppl), 570–570. https://doi.org/10.1200/jco.2019.37.4_suppl.570

The impact of the immune microenvironment in patients with GEP-NETs.

Journal of Clinical Oncology / Feb 01, 2019

Baretti, M., Zhu, Q., Zahurak, M., Pawlik, T. M., Anders, R. A., & De Jesus-Acosta, A. (2019). The impact of the immune microenvironment in patients with GEP-NETs. Journal of Clinical Oncology, 37(4_suppl), 267–267. https://doi.org/10.1200/jco.2019.37.4_suppl.267

Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram

Annals of Oncology / Oct 01, 2017

Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008

Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram

Annals of Oncology / Oct 01, 2017

Morano, F., Pietrantonio, F., Barretta, F., Fanotto, V., Niger, M., Nichetti, F., Bergamo, F., Silvestris, N., Fornaro, L., Bordonaro, R., Baretti, M., Santini, D., Tomasello, G., Antonuzzo, L., Noventa, S., Avallone, A., Di Donato, S., Maiello, E., De Vita, F., & Aprile, G. (2017). Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Annals of Oncology, 28, vi46–vi47. https://doi.org/10.1093/annonc/mdx425.008

P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice

Journal of Thoracic Oncology / Jan 01, 2017

Mountzios, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., Toschi, L., & Metro, G. (2017). P1.07-018 Incidence of Brain Recurrence and Survival Outcomes in High-Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice. Journal of Thoracic Oncology, 12(1), S706–S707. https://doi.org/10.1016/j.jtho.2016.11.930

Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study

Annals of Oncology / Oct 01, 2016

Baretti, M., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Rimassa, L., & Santoro, A. (2016). Evaluation of Charlson comorbidity index as predictor of survival in stage II-III colorectal cancer patients treated with surgery and neoadjuvant/adjuvant chemotherapy: A single Institution observational study. Annals of Oncology, 27, vi183. https://doi.org/10.1093/annonc/mdw370.104

Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study

Annals of Oncology / Sep 01, 2016

Baretti, M., Giordano, L., Rimassa, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., Personeni, N., & Santoro, A. (2016). Prognostic impact of comorbidity in stage II-III colorectal cancer (CRC) patients treated with surgery and neoadjuvant/adjuvant chemotherapy: a single Institution observational study. Annals of Oncology, 27, iv48. https://doi.org/10.1093/annonc/mdw335.29

An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort

Annals of Oncology / Sep 01, 2016

Bozzarelli, S., Rimassa, L., Giordano, L., Sala, S., Tronconi, M. C., Baretti, M., Personeni, N., Pressiani, T., & Santoro, A. (2016). An open-label phase II study (RESOUND) of Regorafenib in patients with refractory solid tumors. Results of pancreatic cohort. Annals of Oncology, 27, iv25. https://doi.org/10.1093/annonc/mdw333.29

Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience

Annals of Oncology / Sep 01, 2016

Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, E. S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). Palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer: a large Italian experience. Annals of Oncology, 27, iv18. https://doi.org/10.1093/annonc/mdw333.03

P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer

Annals of Oncology / Jun 01, 2016

Fanotto, V., Fontanella, C., Cordio, S., Pasquini, G., Baretti, M., Filippi, R., Rosati, G., Santini, D., Giampieri, R., Di Donato, S., Tomasello, G., Brunetti, O., Caporale, M., Bergamo, F., Avallone, A., Scartozzi, M., Lutrino, S., Melisi, D., Antonuzzo, L., … Aprile, G. (2016). P-173 Outcomes of palliative gastrectomy in 549 asymptomatic patients with advanced gastric cancer. Annals of Oncology, 27, ii51. https://doi.org/10.1093/annonc/mdw199.167

O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC)

Annals of Oncology / Jun 01, 2016

Pietrantonio, F., Cremolini, C., Rimassa, L., Lonardi, S., Mennitto, A., Morano, F., Iacono, D., Berenato, R., Caporale, M., Niger, M., Marmorino, F., Bozzarelli, S., Bergamo, F., Rossini, D., Baretti, M., Battaglin, F., Bonotto, M., Loupakis, F., de Braud, F., & Miceli, R. (2016). O-013 A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC). Annals of Oncology, 27, ii122. https://doi.org/10.1093/annonc/mdw198.13

Third-Line Folfiri in Metastatic Gastric Cancer Patients

Annals of Oncology / Sep 01, 2012

Caparello, C., Vasile, E., Lencioni, M., Fabrini, M. G., Lucchesi, M., Ginocchi, L., Caponi, S., Santi, S., Ricci, S., & Falcone, A. (2012). Third-Line Folfiri in Metastatic Gastric Cancer Patients. Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33344-5

Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC)

Annals of Oncology / Sep 01, 2012

Caparello, C., Lencioni, M., Vasile, E., Caponi, S., Santi, S., Fabrini, M. G., Ginocchi, L., Lucchesi, M., Ricci, S., & Falcone, A. (2012). Second-Line Docetaxel (D) in Metastatic Gastric Cancer (MGC). Annals of Oncology, 23, ix251. https://doi.org/10.1016/s0923-7534(20)33343-3

Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.

Journal of Clinical Oncology / May 20, 2010

Vasile, E., Caponi, S., Lucchesi, M., Del Chiaro, M., Funel, N., Ginocchi, L., Campani, D., Falcone, A., Boggi, U., & Mosca, F. (2010). Evaluation of prognostic factors and of the role of adjuvant chemotherapy in patients with invasive carcinoma derived from intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. Journal of Clinical Oncology, 28(15_suppl), e14605–e14605. https://doi.org/10.1200/jco.2010.28.15_suppl.e14605

Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study

Clinical Colorectal Cancer / Sep 01, 2018

Baretti, M., Rimassa, L., Personeni, N., Giordano, L., Tronconi, M. C., Pressiani, T., Bozzarelli, S., & Santoro, A. (2018). Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study. Clinical Colorectal Cancer, 17(3), e489–e498. https://doi.org/10.1016/j.clcc.2018.03.010

Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?

Cancer Biology &amp; Therapy / Apr 13, 2018

Baretti, M., Personeni, N., Destro, A., Santoro, A., & Rimassa, L. (2018). Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? Cancer Biology &amp; Therapy, 19(8), 659–663. https://doi.org/10.1080/15384047.2018.1450117

Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications

Gastric Cancer / Aug 16, 2016

Personeni, N., Baretti, M., Bozzarelli, S., Spaggiari, P., Rubino, L., Tronconi, M. C., Fumagalli Romario, U., Rosati, R., Giordano, L., Roncalli, M., Santoro, A., & Rimassa, L. (2016). Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 20(3), 428–437. https://doi.org/10.1007/s10120-016-0625-1

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice

Lung Cancer / May 01, 2016

Metro, G., Ricciuti, B., Chiari, R., Baretti, M., Falcinelli, L., Giannarelli, D., Sidoni, A., Mountzios, G., Crinò, L., Bellezza, G., Rebonato, A., Ferolla, P., & Toschi, L. (2016). Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice. Lung Cancer, 95, 82–87. https://doi.org/10.1016/j.lungcan.2016.03.006

Ramy Ayoub

Ph.D. Candidate, University of Toronto | SickKids Hospital
Most Relevant Research Interests
Oncology
Other Research Interests (15)
neuro-oncology
mouse imaging
cancer therapy
normal tissue toxicity
General Biochemistry, Genetics and Molecular Biology
And 10 more
About
Ramy Ayoub is a PhD candidate at the University of Toronto in the department of Medical Biophysics. His research focuses on the development of treatment strategies to limit long-term negative complications in brain tumour survivors treated with radiation therapy. Ramy addresses his thesis work by conducting genetic, pharmacological, and neuroimaging studies on mouse models for paediatric radiotherapy. Ramy has authored numerous scientific publications and is a recipient of several awards, including the Brain Star award for excellence in Canadian research. Ramy has passion for advancing science innovation through collaborative efforts across academia and industry.
Most Relevant Publications (1+)

7 total publications

QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY

Neuro-Oncology / Jun 01, 2018

Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634

Timothy Sears

PhD student, Bioinformatics, UC San Diego
Most Relevant Research Interests
Oncology
Oncology
Other Research Interests (14)
bioinformatics
cancer genomics
immunotherapy
General Biochemistry, Genetics and Molecular Biology
General Medicine
And 9 more
About
3rd Year PhD student at UC San Diego with large corporate & high-level academic experience.
Most Relevant Publications (3+)

7 total publications

Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis

Clinical Cancer Research / May 02, 2023

Bui, N. Q., Nemat-Gorgani, N., Subramanian, A., Torres, I. A., Lohman, M., Sears, T. J., van de Rijn, M., Charville, G. W., Becker, H.-C., Wang, D. S., Hwang, G. L., Ganjoo, K. N., & Moding, E. J. (2023). Monitoring Sarcoma Response to Immune Checkpoint Inhibition and Local Cryotherapy with Circulating Tumor DNA Analysis. Clinical Cancer Research, 29(14), 2612–2620. https://doi.org/10.1158/1078-0432.ccr-23-0250

Abstract 5960: Identification and validation of sarcoma cellular ecosystems associated with prognosis and predictive of immunotherapy response

Cancer Research / Apr 04, 2023

Subramanian, A., Nemat-Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G. P., Sears, T. J., Somani, A., Luca, B. A., Zhou, M. Y., Bradic, M., Torres, I. A., Oladipo, E., New, C., Kenney, D. E., Avedian, R. S., Steffner, R. J., Binkley, M. S., Mohler, D. G., Tap, W. D., D’Angelo, S. P., … Moding, E. J. (2023). Abstract 5960: Identification and validation of sarcoma cellular ecosystems associated with prognosis and predictive of immunotherapy response. Cancer Research, 83(7_Supplement), 5960–5960. https://doi.org/10.1158/1538-7445.am2023-5960

Abstract 3825: Germline modifiers of the tumor immune microenvironment reveal drivers of immunotherapy response

Cancer Research / Jun 15, 2022

Pagadala, M., Wu, V., Pérez-Guijarro, E., Kim, H., Castro, A., Talwar, J., Gonzalez-Colin, C., Cao, S., Schmiedel, B. J., Sears, T., Goudarzi, S., Kirani, D., Salem, R. M., Morris, G. P., Harismendy, O., Patel, S. P., Mesirov, J. P., Zanetti, M., Day, C.-P., … Carter, H. (2022). Abstract 3825: Germline modifiers of the tumor immune microenvironment reveal drivers of immunotherapy response. Cancer Research, 82(12_Supplement), 3825–3825. https://doi.org/10.1158/1538-7445.am2022-3825

Amir Manbachi

Co-director and Founder of the Johns Hopkins HEPIUS Innovation Lab
Most Relevant Research Interests
Oncology
Other Research Interests (56)
Biomedical Engineering
Engineering Design
Medical Devices
Ultrasound
Neurosurgery
And 51 more
Most Relevant Publications (3+)

92 total publications

Reusable Core Needle Biopsy Device for Low-Resource Settings

Journal of Global Oncology / Oct 01, 2018

Callanan, M., Zawicki, V., Hinson, L., Lee, M., Triantis, S., Manbachi, A., & Harvey, S. (2018). Reusable Core Needle Biopsy Device for Low-Resource Settings. Journal of Global Oncology, 4(Supplement 3), 47s–47s. https://doi.org/10.1200/jgo.18.10550

Towards standardization of the parameters for opening the blood–brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models

Frontiers in Oncology / Feb 16, 2023

Thombre, R., Mess, G., Kempski Leadingham, K. M., Kapoor, S., Hersh, A., Acord, M., Kaovasia, T., Theodore, N., Tyler, B., & Manbachi, A. (2023). Towards standardization of the parameters for opening the blood–brain barrier with focused ultrasound to treat glioblastoma multiforme: A systematic review of the devices, animal models, and therapeutic compounds used in rodent tumor models. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1072780

Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier

Cancers / Oct 08, 2022

Hersh, A. M., Bhimreddy, M., Weber-Levine, C., Jiang, K., Alomari, S., Theodore, N., Manbachi, A., & Tyler, B. M. (2022). Applications of Focused Ultrasound for the Treatment of Glioblastoma: A New Frontier. Cancers, 14(19), 4920. https://doi.org/10.3390/cancers14194920

Olivier Saulnier

The Hospital for Sick Children
Most Relevant Research Interests
Oncology
Other Research Interests (17)
Bioinformatics - single-cell omics
Neurology (clinical)
General Biochemistry, Genetics and Molecular Biology
Cancer Research
General Physics and Astronomy
And 12 more
Most Relevant Publications (6+)

25 total publications

EPEN-52. METABOLIC REGULATION OF THE EPIGENOME DRIVES LETHAL INFANTILE EPENDYMOMA

Neuro-Oncology / Dec 01, 2020

Kumar, S., Michealraj, A., Kim, L., Rich, J., & Taylor, M. (2020). EPEN-52. METABOLIC REGULATION OF THE EPIGENOME DRIVES LETHAL INFANTILE EPENDYMOMA. Neuro-Oncology, 22(Supplement_3), iii318–iii318. https://doi.org/10.1093/neuonc/noaa222.185

MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA

Neuro-Oncology / Jun 01, 2023

Saulnier, O., Zagozewski, J., Liang, L., Hendrikse, L. D., Gordon, V., Aldinger, K. A., Haldipur, P., Borlase, S., Coudiere-Morrison, L., Layug, P., Cai, T., Porter, C. J., Richard, S., Doble, B. W., Millen, K. J., Taylor, M. D., & Werbowetski-Ogilvie, T. E. (2023). MDB-21. THE OTX2-REGULATED ALTERNATIVE SPLICING LANDSCAPE CONTROLS DIFFERENTIATION AND RECONSTITUTES THE DEVELOPMENTAL ORIGINS OF GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i66–i67. https://doi.org/10.1093/neuonc/noad073.254

BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA

Neuro-Oncology / Jun 01, 2023

Llaguno, S. A., Nazarenko, I., Chen, Y., Sun, D., Gudenas, B., Saulnier, O., Rocca, G. L., Pedraza, A., Burns, D., Bale, T., Ventura, A., Northcott, P., Taylor, M., & Parada, L. (2023). BIOL-23. LOSS OF MICRORNAS COOPERATES WITH TUMOR SUPPRESSORS TO INITIATE MYC-DEPENDENT METASTATIC MEDULLOBLASTOMA. Neuro-Oncology, 25(Supplement_1), i11–i11. https://doi.org/10.1093/neuonc/noad073.042

Abstract IA009: Oncogenic transcription factors drive highly tumor-specific LincRNA

Clinical Cancer Research / Sep 15, 2022

Delattre, O., Vibert, J., Saulnier, O., & Waterfall, J. (2022). Abstract IA009: Oncogenic transcription factors drive highly tumor-specific LincRNA. Clinical Cancer Research, 28(18_Supplement), IA009–IA009. https://doi.org/10.1158/1557-3265.sarcomas22-ia009

The LIN28B–let‐7–PBK pathway is essential for group 3 medulloblastoma tumor growth and survival

Molecular Oncology / Aug 07, 2023

Shahab, S. W., Roggeveen, C. M., Sun, J., Kunhiraman, H., McSwain, L. F., Juraschka, K., Kumar, S. A., Saulnier, O., Taylor, M. D., Schniederjan, M., Schnepp, R. W., MacDonald, T. J., & Kenney, A. M. (2023). The <scp>LIN28B</scp>–let‐7–<scp>PBK</scp> pathway is essential for group 3 medulloblastoma tumor growth and survival. Molecular Oncology. Portico. https://doi.org/10.1002/1878-0261.13477

Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma

Cancer Discovery / Jan 17, 2023

Ye, Z., Ai, X., Yang, K., Yang, Z., Fei, F., Liao, X., Qiu, Z., Gimple, R. C., Yuan, H., Huang, H., Gong, Y., Xiao, C., Yue, J., Huang, L., Saulnier, O., Wang, W., Zhang, P., Dai, L., Wang, X., … Zhou, S. (2023). Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma. Cancer Discovery, 13(4), 974–1001. https://doi.org/10.1158/2159-8290.cd-22-0455

AMAN SHARMA

Postdoctoral Research Fellow, Memorial Sloan Kettering Cancer Center.
Most Relevant Research Interests
Oncology
Other Research Interests (11)
nuclear hormone receptors
DNA damage and repair
R loops
G quadruplex
homologous recombination
And 6 more
Most Relevant Publications (4+)

8 total publications

Inter-Individual Variation in Response to Estrogen in Human Breast Explants

Journal of Mammary Gland Biology and Neoplasia / Mar 01, 2020

Dunphy, K. A., Black, A. L., Roberts, A. L., Sharma, A., Li, Z., Suresh, S., Browne, E. P., Arcaro, K. F., Ser-Dolansky, J., Bigelow, C., Troester, M. A., Schneider, S. S., Makari-Judson, G., Crisi, G. M., & Jerry, D. J. (2020). Inter-Individual Variation in Response to Estrogen in Human Breast Explants. Journal of Mammary Gland Biology and Neoplasia, 25(1), 51–68. https://doi.org/10.1007/s10911-020-09446-3

Genetic modifiers of p53: opportunities for breast cancer therapies

Oncotarget / Jan 12, 2023

Majhi, P. D., Sharma, A., & Jerry, D. J. (2023). Genetic modifiers of p53: opportunities for breast cancer therapies. Oncotarget, 14(1), 236–241. https://doi.org/10.18632/oncotarget.28387

Abstract P1-07-10: Estrogen-stimulated DNA damage in mammary epithelium varies among strains of rodents and women

Cancer Research / Feb 15, 2022

Dunphy, K. A., Sharma, A., Majhi, P., Schneider, S. S., Crisi, G. M., Makari-Judson, G., & Jerry, D. J. (2022). Abstract P1-07-10: Estrogen-stimulated DNA damage in mammary epithelium varies among strains of rodents and women. Cancer Research, 82(4_Supplement), P1-07-10-P1-07–10. https://doi.org/10.1158/1538-7445.sabcs21-p1-07-10

Abstract 3750: Xenoestrogens cause estrogen receptor-dependent R-loop formation and DNA damage

Cancer Research / Jul 01, 2018

Dunphy, K. A., Majhi, P. D., Sharma, A., Roberts, A. L., Daniele, E. A., Schneider, S. S., & Jerry, D. J. (2018). Abstract 3750: Xenoestrogens cause estrogen receptor-dependent R-loop formation and DNA damage. Cancer Research, 78(13_Supplement), 3750–3750. https://doi.org/10.1158/1538-7445.am2018-3750

Mehrdad Sheikhvatan

Iran University of Medical Sciences
Most Relevant Research Interests
Oncology
Other Research Interests (58)
Molecular Cardiogenetic
Obstetrics and Gynecology
Neurology (clinical)
Otorhinolaryngology
Gastroenterology
And 53 more
Most Relevant Publications (1+)

90 total publications

Comparison of the efficacy of intravenous tranexamic acid with and without topical administration versus placebo in urgent endoscopy rate for acute gastrointestinal bleeding: A double-blind randomized controlled trial

United European Gastroenterology Journal / Jun 20, 2017

Tavakoli, N., Mokhtare, M., Agah, S., Azizi, A., Masoodi, M., Amiri, H., Sheikhvatan, M., Syedsalehi, B., Behnam, B., Arabahmadi, M., & Mehrazi, M. (2017). Comparison of the efficacy of intravenous tranexamic acid with and without topical administration versus placebo in urgent endoscopy rate for acute gastrointestinal bleeding: A double-blind randomized controlled trial. United European Gastroenterology Journal, 6(1), 46–54. https://doi.org/10.1177/2050640617714940

Example oncology projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on oncology?

Development of Targeted Cancer Therapies

An Oncology expert can collaborate with a pharmaceutical company to develop targeted therapies that specifically attack cancer cells, minimizing side effects and improving patient outcomes.

Identification of Biomarkers for Early Cancer Detection

Working with an Oncology researcher, a diagnostic company can identify biomarkers that indicate the presence of cancer at an early stage, enabling early detection and intervention.

Improving Radiation Therapy Techniques

Collaborating with an Oncology expert, a medical device company can enhance radiation therapy techniques, improving precision and minimizing damage to healthy tissues.

Development of Personalized Treatment Plans

An Oncology researcher can assist a healthcare provider in developing personalized treatment plans for cancer patients, considering individual characteristics and genetic profiles.

Exploring Immunotherapy Approaches

Working with an Oncology expert, a biotech company can explore novel immunotherapy approaches for cancer treatment, harnessing the power of the immune system to fight cancer cells.